Commons Sense

House of Commons · Ministers' Questions

NHS Expenditure and EU Negotiations

Tuesday 1 September 2020 · 1 question

Summarised by AI from the official record, so it can contain mistakes.

Read the full transcript on Parliament.uk

At a glance

Answered 1 Partly answered 0 Not answered 0

Key points

  • The Department is implementing a multi-layered approach to guarantee continuity of supply for medicines and medical products.
  • We are assured that supply continuity will be maintained regardless of negotiation outcomes.
  • Customs bureaucracy could lead to increased costs for drugs not produced in the UK, particularly insulin.

Topics (select to filter)

Questions & Answers

Q1 Kirsten Oswald SNP West Tyrone
NHS Brexit
Context

The UK is currently negotiating its future relationship with the EU post-transition period, which could affect NHS spending.

Question

What recent assessment has been made regarding the potential effect on NHS expenditure due to ongoing negotiations with the EU? The hon. Member also inquired about customs bureaucracy leading to increased drug costs for the NHS, particularly for insulin that is not produced in the UK, and noted challenges faced by pharmaceutical firms in rebuilding stockpiles.

Answer from Edward Argar (The Parliamentary Under-Secretary of State for Health and Social Care)

The Department is implementing a multi-layered approach to guarantee continuity of supply for medicines and medical products, regardless of the negotiation outcomes or the transition period end. We are assured that supply continuity will be maintained.

Answered
Was this summary accurate? Tell us

How accurate was this summary? (1 = poor, 5 = spot on)

Get updates like this by email